Articles
AusBiotech wraps up a year in biotechnology
This year Australia’s biotechnology industry can celebrate Christmas knowing that despite the challenges in the sector, companies in Australia can be proud of the year’s achievements. [ + ]
Clinuvel success in Scenesse trial
Clinuvel (ASX:CUV) has shown in a phase IIa trial that its Scenesse implant in combination with UV therapy can aid in the treatment if skin pigmentation condition vitiligo. [ + ]
Annual global biopharmaceutical manufacturing survey is on again
Biopharmaceutical manufacturers and contract manufacturing organisations (CMOs) are invited to participate in the bio-industry's most in-depth, global study: the 10th Annual Biopharmaceutical Manufacturing Report and Survey. [ + ]
Do we live in a computer simulation?
A decade ago, a British philosopher put forth the notion that the universe we live in might in fact be a computer simulation run by our descendants. While that seems far-fetched, perhaps even incomprehensible, a team of physicists at the University of Washington has come up with a potential test to see if the idea holds water. [ + ]
Epigenetics and homosexuality
Is homosexuality genetic? It’s a long-running debate. [ + ]
Mesoblast MPCs used to boost blood cell transplants
Scientists from Mesoblast (ASX:MSB) and the University of Texas have been trialling a method for using Mesoblast's adult stem cells to accelerate the body's adoption of umbilical cord blood stem cell transplants. [ + ]
ABCA gathers for Council’s inaugural meeting
The first meeting of the Agricultural Biotechnology Council of Australia (ABCA) took place in Canberra last week, signalling a new and significant era for Australian agriculture. [ + ]
Alchemia in final stages of demerger
Alchemia (ASX:ACL) has entered a trading halt as it is on the cusp of completing its demerger and spin-off of Audeo Oncology, which prepares for its IPO. [ + ]
BioDiem partner close to filing for vaccine exports
BioDiem (ASX:BDM) partner Serum Institute of India will file for WHO approval in early 2013 to export flu vaccines based on BioDiem's LAIV platform. [ + ]
Sequencing systems resolve genetic mutations in over 4000 blood cancer cases
At the 2012 American Society of Hematology (ASH) Annual Meeting, Roche announced the presentation of results from the large-scale study IRON-II through an international research consortium. Based on next-generation 454 Sequencing Systems from Roche, the study aims to characterise selected genes in individuals with a wide range of haematological malignancies. [ + ]
AusBiotech comments on FSANZ cost recovery plans for health claims applications
AusBiotech has written to Food Standards Australia New Zealand (FSANZ) in response to its consultation on proposed cost recovery arrangements for applications related to health claims, opposing the move. [ + ]
Researcher cuts DNA extraction time from days to hours
Durham University researcher Alice Rowland has benefited from the use of the PowerPlant Pro DNA Isolation kit in extracting DNA from the cells of arctic birch trees. Her investigations of patches of forest in the arctic conditions of Northern Sweden were hampered by slow DNA extraction, until the selection of the kit cut procedures down dramatically. [ + ]
Patrys (ASX:PAB) hits myeloma trial milestone
Patrys (ASX:PAB) has completed the main round of dosing for the first three patients enrolled in a German trial of its PAT-SM6 antibody in multiple myeloma. [ + ]
Graham Kelly back in charge of revamped Novogen
Novogen (ASX:NRT) has acquired cancer drug developer Triaxial and re-appointed founder Dr Graham Kelly as CEO as it completes a three-year restructuring. [ + ]
There’s something lurking out there
Deep in interstellar space there is something lurking. Actually there is lots of something lurking. We know it’s there because of its spectra but we have no idea what it is. [ + ]
